Chris Carswell
@PECjournalEditor in Chief PharmacoEconomics. Past President ISPOR NZ Chapter, ex pharmacist, run and play the piano. UK expat in New Zealand. All views are my own
PharmacoEconomics has a Call For Papers for a themed issue on individual level models link.springer.com/collection…

⟳ Chris Carswell retweeted
A much needed reporting checklist for discrete choice experiments link.springer.com/article/10…
link.springer.comA Reporting Checklist for Discrete Choice Experiments in Health: The DIRECT ChecklistPharmacoEconomics - Reporting standards of discrete choice experiments (DCEs) in health have not kept pace with the growth of this method, with multiple reviews calling for better reporting to...
Seems to me the QALY is so entrenched in many countries it would take a huge effort to move away from it
This tweet is unavailable

⟳ Chris Carswell retweeted
Second, this solo editorial in Pharmacoeconomics, called "Making Models Fit for Purpose: the Importance of Ensuring Stakeholder Involvement". Also available free right here! rdcu.be/dwnP1

⟳ Chris Carswell retweeted
My 'Framework for the Fair Pricing of Medicines' has just been published as a Leading Article by Pharmacoeconomics. This framework proposes a number of advancements to existing approaches for specifying a 'cost-effectiveness threshold' for new medicines. link.springer.com/article/10…
link.springer.comA Framework for the Fair Pricing of MedicinesPharmacoEconomics - As high-cost medicines put increasing pressure on public health care budgets, the need to identify ‘fair’ prices for medicines has never been greater. This paper...

⟳ Chris Carswell retweeted
Including carer outcomes in economic evaluation is important & can reveal unrecognised challenges in HTA decisions. One of these is where patient & carer QALYs point in different directions - work led by @davidjohnmott and colleagues @OHENews @HEU_UoB link.springer.com/article/10…
link.springer.comModelling Spillover Effects on Informal Carers: The Carer QALY TrapPharmacoEconomics - The provision of informal (unpaid) care can impose significant ‘spillover effects’ on carers, and accounting for these effects is consistent with the efficiency and...

⟳ Chris Carswell retweeted
1/3 "Using Age-Specific Values for Pediatric HRQoL in CEA: Is There a Problem to Be Solved? If So, How?" available here👉 tinyurl.com/45xn56sk Really pleased this paper is out - hope it serves to progress the debate! @stolk_elly @MJSculpher @rich_norman @QUOKKA_Research

⟳ Chris Carswell retweeted
Thread update on the QUOKKA project led by the brilliant @nancydevlin1 - huge output from this multi-university project on measuring and valuing child QoL
1/10 Time flies! @QUOKKA_Research is now in its 3rd and final year. Here's a thread with a quick overview of where we're at and what we'll be doing this year!
Terrible grammar is a key sign!
Academic publishing scams are getting very good, having had a paper published yesterday this came through soon after. If it wasn't for the terrible grammar I would have clicked on the link. Be careful out there! I was so pleased I'd been nominated!

⟳ Chris Carswell retweeted
Congratulations @dinaabushanab10 on this massive work on projecting the health and economic burden of CVD among people with type 2 diabetes @claremarquina @JedidiahMorton @PECjournal link.springer.com/article/10…
link.springer.comProjecting the Health and Economic Burden of Cardiovascular Disease Among People with Type 2...PharmacoEconomics - The aim was to project the health and economic outcomes of cardiovascular disease (CVD) among people with type 2 diabetes from Australian public healthcare and societal...

⟳ Chris Carswell retweeted
In preparation for my new class @HarrisPolicy, I asked ChatGPT: “How to conduct cost-effectiveness analysis (CEA)?” ChatGPT provides a very solid high-level summary, and I don’t think I can do a better job. Thoughts? @PeterNeumann11 @Basucally @AnkurFactorial @WrightCensored

⟳ Chris Carswell retweeted
At @ipha's conference. The Minister just mentioned Ireland's €45,000/QALY threshold and that there is an existing pathway for orphan drugs to exceed it. Interesting confirmation of the threshold and that it doesn't always apply.

⟳ Chris Carswell retweeted
@BCNHealth publishes a study reviewing economic evaluations and burden of disease studies of endometriosis #health #review #economic #evaluation #burden #disease #endometriosis #costs #indirect #productivity #losses https://t.co/yR9pQgbgqg

⟳ Chris Carswell retweeted
Antimicrobial resistance or #AMR, as known in short, is a global health crisis. Find out how we're applying a new 'Netflix' style payment model to boost the antimicrobial pipeline, which has already assessed 2 new antimicrobial drugs⬇️ link.springer.com/article/10…
link.springer.comCan the UK ‘Netflix’ Payment Model Boost the Antibacterial Pipeline?Applied Health Economics and Health Policy - The silent pandemic of antimicrobial resistance (AMR) is a global issue needing prompt attention. A comprehensive one-health approach across human and...

⟳ Chris Carswell retweeted
Long shot but are there any health economist out there would would review a journal paper for me? My last PhD by publication paper has been stuck in one journal for 5 months with no reviewers, I think it is now down to me to find one!
No posts match this search.





